

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE**

Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company about the latest business update of the Group that Sirnaomics, Inc., a wholly-owned subsidiary of the Company, has concluded Phase I for test drug STP707 and the formal submission of the Clinical Study Report (“**CSR**”) to the U.S. Food and Drug Administration (“**FDA**”).

The study included adults with advanced, metastatic or inoperable solid tumors (the “**Patients**”) that had spread or could not be removed by surgery, and whose cancer had stopped responding to standard treatments. STP707 demonstrated meaningful clinical activity in the Patients, with some achieving stable disease, slowing progression in a heavily pretreated population with limited treatment options. The Patients received various dosage of STP707 through an intravenous administration. This early phase concluded that STP707 could be given at various doses, with mostly manageable side effects.

The Company believes that completing Phase I and submitting the CSR to the FDA marks a pivotal milestone for STP707. With the CSR submitted, Sirnaomics, Inc. is positioned to initiate discussions with the FDA to define the Phase II development strategy, building on the completion of STP707’s Phase I submission.

This announcement is made by the Company on a voluntary basis. There is no guarantee that the Company will be able to develop, or ultimately market, STP707, successfully. Shareholders and potential investors of the Company should exercise caution and due care when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.
Poon Hung Fai
Chairman and Executive Director

Hong Kong, December 22, 2025

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Mr. Ouyang Yunlong and Dr. Yin Huijun as non-executive Directors, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.